Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.
Cota
D
D
Neuroendocrinology Group, Max-Planck-Institute of Psychiatry, Munich, Germany.
Genghini
S
S
Pasquali
R
R
Pagotto
U
U
D000818:Animals; D002149:Energy Intake / Q000502:physiology; D004734:Energy Metabolism / Q000502:physiology; D005247:Feeding Behavior / Q000502:physiology; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D011955:Receptors, Drug / Q000037:antagonists & inhibitors; D000077285:Rimonabant
D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D011955:Receptors, Drug; D000077285:Rimonabant